Balancing Efficacy and Long-Term Tolerability in Metastatic Castration-Sensitive Prostate Cancer

In this segment, Dr. Graham and Dr. Sokolova focus on the growing importance of long-term tolerability as survival outcomes improve in metastatic castration-sensitive prostate cancer. The discussion centers on how extended follow-up from mCSPC trials has highlighted the need to balance treatment efficacy with cumulative toxicity as patients remain on therapy for longer durations. Dr. Sokolova discusses how long-term adverse effects, patient comorbidities, and functional status factor into treatment selection and continuation over time. Both experts emphasize that optimizing outcomes requires ongoing assessment rather than fixed decisions made at treatment initiation. The conversation also highlights the role of proactive monitoring and timely adjustments to maintain disease control while preserving quality of life. Overall, this segment underscores how long-term tolerability considerations are becoming integral to personalized, sustainable management strategies in mCSPC.